Clinical trials: Bacterial Pneumonia
Bacteremia
Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)
To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.
- Trial name
- DIREBT (NCT01919762)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- T2 Biosystems
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.
- Trial name
- NCT01810861
- Testing
- There is no intervention in this study
- Where
- 32 sites in Turkey (Türkiye)
- Volunteers
- 922 people
- Sponsor
- Pfizer
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.
- Trial name
- NCT05602480
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Community Acquired Bacterial Pneumonia
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- DEFINE-CABP (NCT02679573)
- Testing
- Delafloxacin, Moxifloxacin, Linezolid
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 860 people
- Sponsor
- Melinta Therapeutics, Inc.
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately severe Pneumocystis pneumonia (PCP).
- Conditions
- Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00302341
- Testing
- Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Respiratory Tract Infections, Corona Virus Infection
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Non tuberculous mycobacteria (NTM), Burkholdria spp, Aspergillus in the lung are almost impossible to eradicate with conventional antibiotics. In addition COVID-19 has know current treatment.
- Trial name
- NCT03331445
- Testing
- Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Chris Miller
Community Acquired Pneumonia
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.
- Trial name
- NCT01886053
- Testing
- Faropenem（high dose group）, Faropenem（low-dose group), Ertapenem
- Where
- 9 sites in China
- Volunteers
- 189 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pneumonia, Pneumocystis Carinii, HIV Infections
An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients
To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of aerosol pentamidine when used as a prophylactic agent in patients who have had at least two or more episodes of AIDS-associated…
- Trial name
- NCT00002030
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- Fisons
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Pneumococcal Infections, Streptococcus Pneumoniae Infections
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae Infections, Pneumococcal Pneumonia
- Trial name
- NCT01444352
- Testing
- Pneumococcal vaccine Formulation 1, Pneumococcal vaccine Formulation 2, Pneumococcal vaccine Formulation 3
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB…
- Trial name
- REITAB-2 (NCT05204563)
- Testing
- Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam
- Where
- 35 sites in United States, France and 2 more
- Volunteers
- 450 people
- Sponsor
- Evopoint Biosciences Inc.
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either…
- Trial name
- NCT00370396
- Testing
- Synflorix, Prevenar, Infanrix hexa
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS.
- Trial name
- NCT00002292
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- LyphoMed
Pneumonia, Pneumococcal
Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers
The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.
- Trial name
- NCT04357522
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine, 13-Valent Pneumococcal Conjugate Vaccine
- Where
- 3 sites in China
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of the pneumococcal conjugate vaccine, co-admin with a 1st dose or a 2nd dose of MMRV vaccine at 12-14 or respectively 14-16 months of age…
- Trial name
- NCT00370227
- Testing
- 10 valent pneumococcal conjugate (vaccine)
- Where
- 8 sites in Finland
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Bacterial, Healthy Volunteers
A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1.
- Conditions
- Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
- Trial name
- NCT03803202
- Testing
- ASP3772, PCV13, PPSV23
- Where
- 26 sites in United States
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline